PSMA-Targeting Peptides for Prostate Cancer
Peptide Molecular Imaging
92%
Accuracy of PSMA PET-CT for detecting prostate cancer metastases, compared to 65% with conventional imaging.
Hofman et al., The Lancet, 2020
Hofman et al., The Lancet, 2020
View as imageProstate-specific membrane antigen (PSMA) is a protein found on the surface of nearly all prostate cancer cells. Its expression increases as cancer becomes more aggressive, making it an ideal target for both imaging and therapy. PSMA-targeting ligands, small molecules and peptide-based compounds designed to bind PSMA with high affinity, have transformed prostate cancer management over the past decade. Three PSMA PET tracers are now FDA-approved, and the radioligand therapy Pluvicto (Lu-177-PSMA-617) reduced mortality by 38% in the phase III VISION trial. For the broader context of how peptide-based imaging works across cancer types, see the pillar article on RGD peptide imaging and tumor visualization with PET.
Key Takeaways
- PSMA PET-CT detected prostate cancer metastases with 92% accuracy versus 65% for conventional imaging in a head-to-head prospective trial
- Three FDA-approved PSMA PET tracers (Ga-68 PSMA-11, F-18 DCFPyL, F-18 PSMA-1007) are available for clinical use as of 2025
- Lu-177-PSMA-617 (Pluvicto) reduced overall mortality by 38% and disease progression by 60% in the VISION trial for metastatic castration-resistant prostate cancer
- Peptide-based immunotherapy targeting PSMA epitopes showed immunogenic T-cell responses in preclinical prostate cancer models[1]
- GRPR-targeting peptides (bombesin analogs) complement PSMA imaging, especially in early-stage disease where PSMA expression may be lower[2]
- The theranostic principle (image first, then treat with the same targeting molecule) represents the most advanced clinical application of peptide-targeted medicine
What Is PSMA and Why Does It Matter for Imaging?
PSMA is a transmembrane glycoprotein (also called glutamate carboxypeptidase II or folate hydrolase I) expressed on normal prostate epithelial cells at low levels. In prostate cancer, expression increases 100- to 1,000-fold, and rises further with higher Gleason scores, metastatic disease, and castration resistance. This differential expression creates a molecular target: a ligand that binds PSMA will accumulate preferentially on cancer cells.
The imaging application is straightforward. Attach a radioactive isotope to a PSMA-binding ligand, inject it into a patient, and use PET or SPECT scanning to visualize where the ligand accumulates. Bright spots indicate high PSMA expression, which in the prostate cancer context almost always means cancer.
PSMA-targeting ligands fall into three categories: antibodies, small molecules, and peptide-based compounds. The small molecule inhibitors (like PSMA-617 and DCFPyL) dominate clinical practice because of their favorable pharmacokinetics. Peptide-based approaches are emerging as alternatives and complements, particularly for immunotherapy applications and for targeting other prostate cancer receptors alongside PSMA.
FDA-Approved PSMA PET Tracers
Three PSMA PET tracers have received FDA approval:
Ga-68 PSMA-11 (approved 2020) was the first approved PSMA PET agent. It uses gallium-68, a generator-produced isotope with a 68-minute half-life. The short half-life means imaging must happen within 1-2 hours of injection, but it also means rapid clearance and low radiation dose to the patient.
F-18 DCFPyL (Pylarify, approved 2021) uses fluorine-18, which has a 110-minute half-life and can be produced in a cyclotron and shipped to distant imaging centers. This practical advantage has made it the most widely used PSMA tracer in the United States.
F-18 PSMA-1007 (Posluma, approved 2023) is a third fluorine-18-based tracer with slightly different biodistribution. Its lower urinary excretion may improve visualization of pelvic disease near the bladder.
All three detect prostate cancer with substantially better accuracy than conventional imaging (CT and bone scan). In a prospective multicenter trial, PSMA PET-CT was 92% accurate at detecting metastases compared to 65% for standard imaging, a 27-percentage-point improvement that changes clinical decisions for staging and treatment planning.
The Theranostic Revolution: From Imaging to Treatment
The same PSMA-binding ligand used for diagnosis can deliver therapeutic radiation directly to cancer cells. This is the theranostic principle: diagnose and treat with the same molecule. For a detailed explanation of this approach, see theranostic peptides: diagnose and treat cancer with the same molecule.
Lu-177-PSMA-617 (Pluvicto)
PSMA-617 is a small molecule that binds PSMA with high affinity. When labeled with gallium-68, it serves as a PET imaging agent. When labeled with lutetium-177, it becomes a radioligand therapy. Lutetium-177 emits beta particles that travel approximately 0.7 mm in tissue, enough to kill the cancer cell it is attached to and nearby cells, but not enough to cause widespread collateral damage.
The VISION trial, a randomized phase III study of 831 patients with metastatic castration-resistant prostate cancer, established Pluvicto as a standard treatment. Adding Lu-177-PSMA-617 to standard care reduced overall mortality by 38% (hazard ratio 0.62) and radiographic progression by 60% (hazard ratio 0.40). The FDA approved Pluvicto in March 2022 and expanded its indication in March 2025 to include patients who could defer chemotherapy.
The clinical workflow is inherently peptide-adjacent. Patients first receive a PSMA PET scan to confirm PSMA-positive disease. Only those with adequate PSMA uptake are eligible for Pluvicto. The imaging agent identifies the target; the therapeutic agent destroys it.
How PSMA Theranostics Compares to PRRT
The PSMA theranostic model was built on the earlier success of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors. PRRT uses radiolabeled somatostatin analogs (Lu-177-DOTATATE, marketed as Lutathera) to target somatostatin receptors on neuroendocrine tumor cells. Xu and colleagues reviewed clinical outcomes and toxicity profiles of PRRT across neuroendocrine tumor patients, finding that renal and hematological toxicity were manageable and dose-limiting.[3] Prasad and colleagues addressed the challenge of developing standardized response evaluation criteria for PRRT, noting that morphological imaging response is often delayed after radionuclide therapy.[4]
The key difference: PRRT uses true peptide ligands (somatostatin analogs like octreotide and DOTATATE), while PSMA-617 is a small molecule urea-based inhibitor. The targeting principle is identical, but the chemistry differs. For more on PRRT, see Lutathera: how radioactive peptides treat cancer and PRRT explained.
Peptide-Based Approaches to PSMA Targeting
While small molecules dominate PSMA imaging and therapy, true peptide-based approaches to PSMA targeting are in development, particularly for immunotherapy.
PSMA Peptide Immunotherapy
Huang and colleagues conducted a preclinical assessment of HLA-A*02:01-restricted peptide epitopes derived from PSMA and STEAP1, two prostate cancer-associated antigens.[1] They identified peptide sequences that bind MHC class I molecules and stimulate cytotoxic T-cell responses against prostate cancer cells. This peptide-based immunotherapy approach is fundamentally different from radioligand therapy: instead of delivering radiation to PSMA-positive cells, it trains the immune system to recognize and kill them.
The preclinical data showed immunogenic responses from both PSMA and STEAP1 epitopes. Combining epitopes from multiple antigens may reduce the chance of immune escape, where cancer cells survive by downregulating a single target. This work is at an early stage, but it demonstrates that PSMA can be targeted by peptides in ways beyond imaging and radioligand therapy.
Peptide-Drug Conjugates for Prostate Cancer
Han and colleagues developed MEL-dKLA, an immunomodulatory peptide-drug conjugate that targets and eliminates M2-like tumor-associated macrophages in prostate cancer.[5] The peptide component provides tumor targeting, while the conjugated drug (dKLA, a mitochondria-disrupting peptide) kills the immunosuppressive macrophages that help tumors evade immune surveillance. In preclinical models, MEL-dKLA suppressed prostate cancer progression by reshaping the tumor immune microenvironment. For broader context on this approach, see peptide-drug conjugates in cancer therapy.
GRPR-Targeting Peptides: The PSMA Complement
Gastrin-releasing peptide receptor (GRPR), also called the bombesin receptor, is overexpressed in prostate cancer, breast cancer, and several other solid tumors. GRPR-targeting peptides serve as a complementary imaging approach to PSMA, particularly useful in scenarios where PSMA expression is low or heterogeneous. For more on bombesin-based imaging, see bombesin receptor imaging for prostate and breast cancers.
Bratanovic and colleagues developed ProBOMB2, a novel bombesin derivative radiolabeled for both PET imaging and therapy of GRPR-positive prostate cancer.[2] The peptide showed specific uptake in GRPR-expressing tumors in preclinical models, demonstrating proof of concept for a GRPR-based theranostic parallel to the PSMA model.
Ghosh and colleagues addressed the practical challenge of stabilizing GRPR-targeting imaging pharmaceuticals for clinical use, noting that both PSMA and GRPR are validated targets on prostate cancer and that dual-targeting strategies may improve detection rates.[6] Moreno and colleagues reviewed the entire bombesin peptide family and its receptor subtypes, cataloging applications in cancer imaging, targeting, and treatment across multiple tumor types.[7]
The 68Ga-RM2 GRPR PET tracer has reached clinical trials. In a study of 100 patients with biochemical recurrence, 68Ga-RM2 PET-MRI was positive in 69% of patients versus 40% for MRI alone, with substantially higher per-lesion detection rates (143 versus 96 lesions).
Other Peptide Receptor Targets in Prostate Cancer
PSMA and GRPR are not the only peptide receptor targets being explored for prostate cancer.
VPAC Receptors
Setya and colleagues evaluated VPAC (vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide) receptor positivity as a diagnostic approach for prostate cancer, comparing it to multiparametric MRI.[8] VPAC receptors are peptide hormone receptors found on prostate cancer cells, and the study explored whether their detection in voided urine samples could serve as a non-invasive diagnostic alternative.
Neuropeptide Y Receptors
Tomic and colleagues identified neuropeptide Y receptors 1 and 2 (NPY1R and NPY2R) as molecular targets in prostate and breast cancer therapy.[9] NPY is a 36-amino-acid peptide, and its receptors are overexpressed in multiple cancers. Peptide-based ligands targeting NPY receptors could serve as imaging agents or therapeutic delivery vehicles, though this work remains preclinical.
The Multi-Target Future
The prostate cancer imaging landscape is expanding beyond single-target approaches. PSMA, GRPR, VPAC, and NPY receptors each capture different aspects of tumor biology. A PSMA-negative recurrence might be GRPR-positive. A low-grade cancer with limited PSMA expression might show strong VPAC receptor signal. The peptide imaging toolkit is growing to cover these scenarios. Similar multi-receptor strategies are already established for other cancers. For a parallel example in a different organ, see exendin peptide imaging for insulinomas, where GLP-1 receptor-targeting peptides achieve detection rates that other imaging modalities miss.
Limitations and Unresolved Questions
PSMA-targeted imaging and therapy have limitations that are often understated in clinical discussions.
False negatives. Not all prostate cancers express PSMA. Approximately 5-10% of prostate cancers are PSMA-negative, which means they will not appear on PSMA PET scans and will not respond to PSMA-targeted therapy. Low-grade disease and certain histological variants (neuroendocrine differentiation, small cell) may have low PSMA expression.
False positives. PSMA is also expressed by non-cancerous tissues, including the brain, kidneys, salivary glands, and small intestine. Ganglia, degenerative bone disease, and other benign conditions can produce PSMA uptake on PET imaging, leading to false positive results.
Sensitivity at low PSA. While PSMA PET is superior to conventional imaging at low PSA levels (below 0.5 ng/mL), detection rates still drop significantly at very low PSA, meaning some recurrences are missed.
Salivary gland toxicity. Pluvicto therapy causes xerostomia (dry mouth) because salivary glands express PSMA. This is a dose-limiting toxicity that affects quality of life, and no reliable method to protect salivary glands during treatment has been validated.
Cost and access. PSMA PET scans cost $3,000-5,000, and Pluvicto therapy costs approximately $42,000 per dose (typically 6 doses). Access remains limited to academic medical centers and specialized nuclear medicine facilities.
The Bottom Line
PSMA-targeting ligands have redefined prostate cancer imaging and treatment. Three FDA-approved PET tracers provide superior metastasis detection compared to conventional imaging. The theranostic model, using the same targeting molecule for diagnosis and treatment, reached its fullest expression with Lu-177-PSMA-617 (Pluvicto). True peptide-based approaches to PSMA targeting are emerging in immunotherapy and drug conjugates, while GRPR-targeting peptides provide complementary imaging for cases where PSMA expression is limited.